Enveric Biosciences shares gained over 4% after Gilgamesh Pharmaceuticals withdrew a challenge against the company's psilocybin patent. Enveric confirmed there are no remaining challenges against the patent, which covers new chemical versions for treating mental health disorders like depression and anxiety.